Healthcare >> CEO Interviews >> July 28, 2003

Steven King – Peregrine Pharmaceuticals Inc (pphm)

STEVEN V. KING was appointed President and Chief Executive Officer of Peregrine Pharmaceuticals, Inc., in March 2003 and was previously Chief Operating Officer. Since January 2000 Mr. King has also served as the President of Peregrine's wholly owned contract manufacturing subsidiary, Avid Bioservices. Mr. King joined Peregrine in 1997 in the capacity of Director of Research and Development and has also served as Senior Director of Research and Development and Vice President of Technology and Product Development prior to becoming Chief Operating Officer in August 2002. Mr. King was previously employed at a corporation that was developing vascular targeting agents (VTA) which was acquired by Peregrine in 1997. Mr. King previously worked with Dr. Phillip Thorpe, inventor of the VTA technology, at the University of Texas Southwestern Medical Center at Dallas and is a co-inventor on over 25 US and foreign patent applications in the VTA area. Profile
TWST: Would you begin with an overview of Peregrine Pharmaceuticals and

explain the concept of collateral targeting technologies?

Mr. King: Peregrine is a public company based in Tustin,